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Introduction: Isolated adrenocorticotropic hormone deficiency is an endocrinological disorder characterized by loss
of adrenocorticotropic hormone and resultant adrenal insufficiency. Affected patients often present with fatigue,
anorexia, and hyponatremia. Although the number of reported cases has been recently increasing, isolated
adrenocorticotropic hormone deficiency combined with malignant neoplasia is very rare. Here we describe a
patient with gastric cancer who developed unexpected isolated adrenocorticotropic hormone deficiency during
chemotherapy.
Case presentation: A 72-year-old Japanese man was admitted to our hospital because of febrile neutropenia due
to chemotherapy for gastric cancer recurrence. Although the neutropenia and fever immediately improved, he
became unable to take any oral medications and was bedridden 1 week after admission. His serum sodium level
abruptly decreased to 122mEq/L on the fifth day of hospitalization. We performed endocrinological studies to
investigate the cause of his hyponatremia and plasma hyposmolality. His plasma adrenocorticotropic hormone and
cortisol levels were very low. However, his serum levels of all other anterior pituitary hormones were slightly elevated.
We then performed a corticotropin-releasing hormone test, which showed that neither his plasma adrenocorticotropic
hormone nor cortisol level responded to corticotropin-releasing hormone stimulation. We definitively diagnosed
isolated adrenocorticotropic hormone deficiency based on these findings. Hydrocortisone replacement therapy was
begun at 20mg/day, resulting in a marked improvement in his anorexia and general fatigue within a few days. His
serum sodium level was also normalized immediately after the administration of hydrocortisone. He was discharged
from our hospital on the 50th day of hospitalization.
Conclusions: The present case is the second report of a patient with concurrent isolated adrenocorticotropic hormone
deficiency and gastric cancer and the first report of a patient diagnosed with isolated adrenocorticotropic hormone
deficiency during the course of chemotherapy for a solid malignant neoplasm. Although the symptoms and signs
described in the present report are common observations during chemotherapy, it is important to consider not only
the adverse effects of antineoplastic agents, but also isolated adrenocorticotropic hormone deficiency as a differential
diagnosis. Hydrocortisone replacement therapy for isolated adrenocorticotropic hormone deficiency effectively avoids
the unnecessary cessation of chemotherapy.
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Table 1 Laboratory data on admission
WBC 1970 /μL ALP 107 IU/L
Neutrophil 350 /μL γ-GTP 9 IU/L
RBC 404 × 104 /μL AST 26 IU/L
Hb 11.4 g/dL ALT 11 IU/L
Bt 35.5 % LDH 187 IU/L
P1t 19.9 × 104 /μL Amy 31 IU/L
T-bil 0.8 mg/dL
BUN 5 mg/dL TP 6.0 g/dL
Cre 0.66 mg/dL Alp 3.6 g/dL
Na 141 mEq/L CRP 3.1 mg/dL





Abbreviations: γ-GTP γ-glutamyltransferase, ALP alkaline phosphatase, ALT
alanine aminotransferase, Amy amylase, AST aspartate aminotransferase, BUN
blood urea nitrogen, CA125 cancer antigen 125, CA19-9 carbohydrate antigen
19-9, CEA carcinoembryonic antigen, Cl chlorine, Cre creatinine, CRP C-reactive
protein, Hb hemoglobin, K potassium, LDH lactate dehydrogenase, Na sodium,
Plt platelet, RBC red blood cell, T-bil total-bilirubin, TP total protein, WBC white
blood cell.
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Adrenocorticotropic hormone (ACTH) is released from
the anterior pituitary gland and is an important hormone
of the hypothalamic–pituitary–adrenocortical axis. Isolated
ACTH deficiency (IAD) was first reported by Steinberg
et al. in 1954 [1]. The decline in production and secretion
of ACTH causes chronic secondary adrenocortical insuffi-
ciency, and affected patients often present with anorexia,
general fatigue, unconsciousness, and hyponatremia. The
diagnosis of IAD usually follows manifestation of adrenal
insufficiency under stress, but is hindered by the complete
lack of specific symptoms and paucity of measurable
signs.
Although the number of diagnosed cases of IAD is in-
creasing because knowledge of the disease and perform-
ance of detailed endocrinology testing have become
more widespread [2], IAD in combination with malig-
nant neoplasia is very rare [3,4]. Here we describe a pa-
tient with gastric cancer who developed unexpected IAD
during chemotherapy.
Case presentation
A 72-year-old Japanese man underwent distal gastrectomy
with D2 lymph node dissection for advanced gastric can-
cer 3 years ago. According to the Union for International
Cancer Control tumor, node, metastasis classification, the
stage of cancer was T3N2M0 (stage IIIA). After surgery,
he received adjuvant chemotherapy with S-1 (TS-1®; Taiho
Pharmaceutical Company, Tokyo, Japan) at 120mg/day
(4 weeks on, 2 weeks off). Six months after the completion
of adjuvant chemotherapy, follow-up computed tomog-
raphy (CT) revealed ascites and enlarged para-aortic
lymph nodes, and his serum carcinoembryonic antigen
level was elevated at 10.9ng/mL. Staging laparoscopy was
then performed and revealed peritoneal metastasis of his
gastric cancer. Then, weekly paclitaxel (Taxol®; Bristol-
Myers Squibb, New York, NY, USA) at 80mg/m2 (3 weeks
of administration followed by 1 week of withdrawal) was
begun as first-line treatment of the peritoneal and lymph
node recurrence. After four courses of chemotherapy, his
serum carcinoembryonic antigen level normalized and CT
showed reduction of his para-aortic lymph nodes and dis-
appearance of the ascites.
He developed general fatigue and anorexia soon after
completion of seven courses of the above-described che-
motherapy. He was then transferred to the out-patient de-
partment for a thorough examination. On admission, he
was alert with a blood pressure of 110/53mmHg, heart
rate of 64 beats per minute, and high body temperature of
38.5°C. His height was 178.5cm, body weight was 60.2kg,
and body mass index was 22.3kg/m2. No pigmentation
was noted in his skin or oral mucosa. The pubic and axil-
lary hair were normal. No abnormal findings were elicited
by the chest and abdominal physical examination.Hematological examination showed leukopenia (white
blood cell count, 1.97 × 103/μL), neutropenia (neutro-
phil count, 350/μL), a hemoglobin level of 11.4g/dL, and
a platelet level of 199 × 103/μL. Biochemical examin-
ation showed a slightly elevated C-reactive protein level
(3.1mg/dL) and a normal blood glucose level (101mg/dL).
His serum electrolyte levels were normal at the time of ad-
mission (Table 1). Chest and abdominal CT showed no
progression of the lymph node metastasis or ascites and
no obvious focus of infection.
He was admitted to our hospital with a diagnosis of febrile
neutropenia. The neutropenia was immediately improved
by the administration of granulocyte colony-stimulating
factor, and his fever decreased 3 days after admission. By
contrast, his anorexia and general fatigue gradually wors-
ened. He was unable to take any oral medications and be-
came bedridden. One week after admission, his Eastern
Cooperative Oncology Group performance status dete-
riorated from 2 to 4. In addition, on the fifth day of
hospitalization, his serum sodium level abruptly decreased
to 122mEq/L, serum osmolality was 239mOsm/kg, and
serum creatinine was 0.69mg/dL. His urine osmolality
(482mOsm/kg) was greater than that of plasma (Table 2).
We initially restricted his fluid intake to 1000mL/day be-
cause we suspected syndrome of inappropriate secretion
of antidiuretic hormone (SIADH) as the cause of the
hyponatremia. However, his serum sodium level did not
normalize despite these treatments. We concurrently per-
formed endocrinological studies in the rest position to
Table 2 Laboratory data during hospitalization
Blood Urine
Na 122 mEq/L Urine osmolality 482 mOsm/L
Serum osmolality 239 mOsm/L Na 198 mEq/L
Cre 0.70 mg/dL Cre 80 mg/dL
FENa 0.014 %
Abbreviations: Cre creatinine, FENa fractional excretion of sodium, Na sodium.
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molality. As shown in Table 3, his early morning plasma
ACTH level (<5pg/mL) and cortisol level (4.6μg/mL) were
very low. However, the plasma levels of all other anterior
pituitary hormones, including follicle-stimulating hor-
mone, luteinizing hormone, prolactin, thyroid-stimulating
hormone, and growth hormone, were slightly elevated.
His serum-free triiodothyronine and serum-free thyroxine
levels were also normal. Because the endocrinological
findings led us to suspect that his hyponatremia and
plasma hyposmolality were caused by ACTH deficiency,
we performed a acorticotropin-releasing hormone (CRH)
test, which showed that his plasma ACTH and cortisol
levels did not respond to CRH stimulation. Antipituitary,
antithyroid peroxidase antibodies, and antinuclear antibodies
were negative in the immunological examinations.
CT and magnetic resonance imaging showed no space-
occupying lesion or atrophic change in his pituitary
gland or hypothalamus (Figure 1).
Because we definitively diagnosed IAD based on these
findings, hydrocortisone replacement therapy was com-
menced at 20mg/day and gradually increased to 30mg/day,Table 3 Hormonal laboratory data
Reference range
ACTH <5.0 pg/mL (7.4–55.7)
TSH 4.63 μU/mL (0.24–3.70)
LH 23.2 mIU/mL (1.22–7.05)
FSH 31.1 mIU/mL (2.00–8.30)
GH 3.23 ng/mL (<0.42)
PRL 44.38 ng/mL (3.58–12.78)
Renin 2.1 pg/mL (0.3–2.9) A
Somatomedin C 68 ng/mL (42–250)
Cortisol 0.4 μg/dL (4.0–18.3)
DHEA-S 10 ng/mL (140–2240)
Aldosterone 59.0 pg/mL (29.9–159)
CRH* test (human corticorelin 100μg i.v.)
Minutes 0 15
ACTH (pg/mL) 5.3 5.8
Cortisol (μg/dL) <1.0 <1.0
Abbreviations: ACTH adrenocorticotropic hormone, CRH corticotropin-releasing horm
hormone, FT3 free triiodothyronine, FT4 free thyroxine, GH growth hormone, i.v. int
TPO ab thyroid peroxidase antibody, TSH thyroid-stimulating hormone.resulting in a marked improvement of his anorexia and
general fatigue within a few days. His serum sodium level
was also normalized immediately after the administration
of hydrocortisone. His performance status returned to the
prehospital state, and he was discharged from our hospital
on the 50th day of hospitalization (Figure 2). He then
underwent out-patient chemotherapy with hydrocortisone
replacement. He remains alive without progression of the
metastatic lesions 6 months after discharge.
Discussion
We have described a case of IAD in a patient with gas-
tric cancer undergoing chemotherapy. He was diagnosed
based on a decrease in his ACTH and cortisol blood
concentrations and the lack of adequate response of
ACTH and cortisol levels to CRH administration.
Although the number of diagnosed cases of IAD is in-
creasing, patients with concurrent IAD and malignant
neoplasms are very rare. Only one patient with acute
lymphoblastic leukemia and one with gastric cancer have
been previously reported [3,4]. Kamiya and Murakami re-
ported a type 2 diabetic patient with concurrent IAD and
gastric cancer who was positive for antipituitary antibody
and had empty sella [4]. To the best of our knowledge, the
present case is the second report of a patient with concur-
rent IAD and gastric cancer and the first report of a patient
diagnosed as IAD during the course of chemotherapy for
a solid malignant neoplasm.
Although the etiology of IAD remains uncertain in
most cases, the main causes of IAD are considered to be
autoimmune processes, congenital and genetic effects,Reference range
FT3 1.6 pg/mL (2.4–4.3)
FT4 1.0 ng/dL (0.9–1.8)
TPO ab <10.0 IU/mL (<28.0)
Tg ab 5.1 IU/mL (<16.0)
Urinary cortisol Not detected μg/day (11–80)
ntipituitary antibody (−) (−)
30 60 90 120
5.6 6.0 5.1 5.4
<1.0 <1.0 <1.0 <1.0
one, DHEA-S dehydroepiandrosterone sulfate, FSH follicle-stimulating
ravenous, LH luteinizing hormone, PRL prolactin, Tg ab thyroglobulin antibody,
Figure 1 Magnetic resonance imaging after the onset of isolated adrenocorticotropic hormone deficiency. Magnetic resonance imaging
showed no space-occupying lesions in the pituitary gland or hypothalamus.
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ery, and hypothalamic lesions secondary to birth trauma
or head injury. IAD has been especially well described in
combination with various autoimmune disorders, such
as Graves’ disease [5], Crohn’s disease [6], Hashimoto’s
thyroiditis [7], myasthenia gravis [8], and type 1 diabetes
mellitus [9]. In addition, 48% of patients with IAD were
positive for antipituitary antibody in one report [10].
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or family history of these autoimmune disorders. In
addition, findings of brain CT and pituitary magnetic
resonance imaging showed no abnormality such as a
tumor, infarction, trauma, or inflammation.
However, it has been reported that powerful stressors
such as external wounds, infections, surgery, or bleeding
can trigger acute adrenal insufficiency [11]. Although it is
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speculate that the stress of febrile neutropenia, which was
a severe adverse effect of chemotherapy, might have trig-
gered the onset of IAD because the patient had undergone
gastric cancer treatment without IAD symptoms for more
than 2 years.
Nausea, vomiting, and general fatigue are the most
common symptoms of adrenal insufficiency and are seen
in more than 90% of patients [12]. Hyponatremia with-
out hyperkalemia is regarded as one of the clinical fea-
tures of IAD [13]. These symptoms of IAD are quite
similar to the adverse effects of antineoplastic agents;
therefore, the diagnosis of IAD was difficult in the
present case. Thus, it is possible that a substantial num-
ber of patients with undiagnosed IAD undergo chemo-
therapy because the clinical features of IAD are similar
to the adverse effects of chemotherapy.
Hyponatremia is rare in patients with central adreno-
cortical insufficiency because the sodium balance is
mainly regulated by the renin-angiotensin system. How-
ever, it is well known that longstanding chronic adrenal
insufficiency without hydrocortisone replacement in-
duces impaired mineralocorticoid secretion. In general,
SIADH is the most probable cause of hyponatremia and
hyposmolality due to antineoplastic agents. It is important
to distinguish SIADH from other endocrine disorders,
especially adrenal insufficiency, in patients undergoing
chemotherapy.
Hyponatremia in patients with adrenal insufficiency
may occur as a result of the inability to excrete a water
load, a syndrome that resembles SIADH [14]. Indeed, we
initially suspected SIADH and restricted the patient’s
fluid intake, which was not effective in the treatment of
hyponatremia. Instead, the administration of hydrocorti-
sone after the diagnosis of IAD immediately improved
not only his hyponatremia, but also his generalized fa-
tigue and anorexia. Although these symptoms and signs
are common observations during chemotherapy, it is
important to consider not only the adverse effects of
antineoplastic agents, but also IAD as a differential
diagnosis. Hydrocortisone replacement for the treat-
ment of IAD effectively avoids the unnecessary cessa-
tion of chemotherapy.
Conclusions
In conclusion, we have described a patient with gastric
cancer who was diagnosed with IAD during the course
of chemotherapy. To the best of our knowledge, this is
the first report of IAD in relation to chemotherapy for a
solid cancer.
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